Article Contents ::
- 1 The Brand Name NIFELAT Has Generic Salt :: Nifedipine
- 2 NIFELAT Is From Company Cipla Priced :: Rs. 9.25
- 3 NIFELAT have Nifedipine is comes under Sub class Anti Anginals of Main Class Cardiovascular System
- 4 Main Medicine Class:: Cardiovascular System Sub Medicine Class :: Anti Anginals
- 5 Disclaimer ::
- 6 The Information available on this site is for only Informational Purpose , before any use of this information please consult your Doctor .Price of the drugs indicated above may not match to real price due to many possible reasons may , including local taxes etc.. These are only approximate indicative prices of the drug.
The Brand Name NIFELAT Has Generic Salt :: Nifedipine
NIFELAT Is From Company Cipla Priced :: Rs. 9.25
NIFELAT have Nifedipine is comes under Sub class Anti Anginals of Main Class Cardiovascular System
Main Medicine Class:: Cardiovascular System Sub Medicine Class :: Anti Anginals
| Salt Name : OR Generic Name | Form | Price : MRP /Probable | Packing | ||
| Nifedipine | CAP | Rs. 9.25 | 10 |
| Brand Name | Company / Manufacturers | Strength | Unit | Price / 10 |
| NIFELAT | Cipla | 10MG | 10 | Rs. 9.25 |
| Company Brand Name | Salt Combination | Main Medical Class | Sub Medical Class |
| From Cipla :: NIFELAT | Nifedipine | Cardiovascular System | Anti Anginals |
Indications for Drugs ::
Hypertension, Angina pectoris, Raynaud’s syndrome, Stroke prevention
Drug Dose ::
Adult: PO HTN Extended release 10-40 mg twice daily or 20-90 mg once daily. Angina pectoris Extended release 10-40 mg twice daily or 30-90 mg once daily. Liquid-filled cap: 5-20 mg 3 times/day. Raynaud’s syndrome Liquid-filled cap: 5-20 mg 3 times/day.
Contraindication ::
Acute MI, cardiogenic shock, acute unstable angina, treatment of anginal attack in chronic stable angina.
Drug Precautions ::
Hypotension, poor cardiac reserve, heart failure (deterioration has been noted), severe aortic stenosis, hepatic impairment, DM, porphyric patients, pregnancy. Avoid abrupt withdrawal (associated with exacerbation of angina). Discontinue if with ischaemic pain following administration.
Drug Side Effects ::
Peripheral oedema, hypotension, palpitations, tachycardia, flushing, dizziness, headache, nausea, increased micturition frequency, lethargy, eye pain, mental depression, visual disturbances, gingival hyperplasia, myalgia, tremor, impotence, fever, paradoxical increase in ischaemic chest pain during initiation of treatment, rashes, abnormalities in liver function (including cholestasis), GI obstruction in some tablets covered in indigestable membrane.
Pregnancy category ::
3
Drug Mode of Action ::
Nifedipine prevents Ca ion from entering the slow channels of cardiac and smooth muscles during depolarisation, producing peripheral and coronary vasodilatation. It reduces afterload, peripheral resistance and BP; increases coronary blood flow and causes reflex tachycardia. It has little or no effect on cardiac conduction and rarely has negative inotropic activity.
Drug Interactions ::
Enhanced antihypertensive effects w/ other antihypertensives, aldesleukin, and antipsychotics. Concomitant use w/ fentanyl during surgery caused severe hypotension. May modify insulin and glucose responses. Attenuation of tachycardic effect when used w/ benazerpril. Prothrombin time may be increased w/ coumarin anticoagulants. Increased serum levels w/ CYP3A4 inhibitors (e.g. azole antifungals, cimetidine, erythromycin, HIV-protease inhibitors, nefazodone, fluoxetine, quinupristin/dalfopristin). Potentially Fatal: Decreased bioavailability and efficacy w/ strong CYP3A4 inducers (e.g. rifampicin, phenytoin, carbamazepine).
